Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Prostaglandin 15d-PGJ(2) targets PPAR gamma and opioid receptors to prevent muscle hyperalgesia in rats

Full text
Author(s):
Santos, Diogo F. S. [1, 2] ; Melo-Aquino, Bruna [1] ; Jorge, Carolina O. [1] ; Clemente-Napimoga, Juliana T. [3] ; Taylor, Bradley K. [2] ; Oliveira-Fusaro, Maria C. G. [1]
Total Authors: 6
Affiliation:
[1] State Univ Campinas UNICAMP, Sch Appl Sci, Hlth, Limeira, SP - Brazil
[2] Univ Pittsburgh, Pittsburgh Ctr Pain Res, Dept Anesthesiol & Perioperat Med, Pittsburgh Project End Opioid Misuse, Pittsburgh, PA - USA
[3] Sao Leopoldo Mand Inst & Res Ctr, Lab Neuroimmune Interface Pain, Lab Immunol & Mol Biol, Campinas, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Neuroreport; v. 32, n. 3, p. 238-243, FEB 3 2021.
Web of Science Citations: 0
Abstract

Pharmacological agents directed to either opioid receptors or peroxisome proliferator-activated receptor gamma (PPAR gamma) at peripheral tissues reduce behavioral signs of persistent pain. Both receptors are expressed in muscle tissue, but the contribution of PPAR gamma activation to muscle pain and its modulation by opioid receptors remains unknown. To address this question, we first tested whether the endogenous PPAR gamma ligand 15d-PGJ(2) would decrease mechanical hyperalgesia induced by carrageenan administration into the gastrocnemius muscle of rats. Next, we used receptor antagonists to determine whether the antihyperalgesic effect of 15-deoxy Delta-12,14-prostaglandin J(2) (15d-PGJ(2)) was PPAR gamma- or opioid receptor-dependent. Three hours after carrageenan, muscle hyperalgesia was quantified with the Randall-Selitto test. 15d-PGJ(2) prevented carrageenan-induced muscle hyperalgesia in a dose-dependent manner. The antihyperalgesic effect of 15d-PGJ(2) was dose-dependently inhibited by either the PPAR gamma antagonist, 2-chloro-5-nitro-N-phenylbenzamide, or by the opioid receptor antagonist, naloxone. We conclude that 15d-PGJ(2) targets PPAR gamma and opioid receptors to prevent muscle hyperalgesia. We suggest that local PPAR gamma receptors are important pharmacological targets for inflammatory muscle pain. Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved. (AU)

FAPESP's process: 11/11064-4 - Development of a new model for the study of muscle hyperalgesia and the involvement of P2X3 and P2X2/3 receptors in muscle hyperalgesia
Grantee:Maria Cláudia Gonçalves de Oliveira
Support Opportunities: Research Grants - Young Investigators Grants